123 related articles for article (PubMed ID: 2856702)
1. Specificity of the serotonergic antagonist ketanserin.
Stott DJ; Robertson JI; Ball SG
J Hypertens Suppl; 1985 Dec; 3(3):S191-3. PubMed ID: 2856702
[TBL] [Abstract][Full Text] [Related]
2. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
[TBL] [Abstract][Full Text] [Related]
3. Ketanserin: systemic and regional hemodynamic characterization of its serotonergic and alpha-adrenergic receptor blocking effects in the pithed SHR.
Scalbert E; Richer C; Giudicelli JF
J Cardiovasc Pharmacol; 1989 Jan; 13(1):94-104. PubMed ID: 2468942
[TBL] [Abstract][Full Text] [Related]
4. Differences in vasodilating action between ketanserin, a 5-HT2-serotonergic receptor antagonist, and terazosin, an alpha 1-adrenoceptor antagonist, in anesthetized rabbits.
Ikeda K; Takata M; Tomoda F; Mikawa M; Iida H; Sasayama S
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S69-72. PubMed ID: 2446076
[TBL] [Abstract][Full Text] [Related]
5. Differences in the acute and chronic antihypertensive mechanism of action of ketanserin in spontaneously hypertensive rats.
Balasubramaniam G; Lee HS; Mah SC
J Pharmacol Exp Ther; 1993 Jan; 264(1):129-34. PubMed ID: 8093720
[TBL] [Abstract][Full Text] [Related]
6. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
Hosie J; Stott DJ; Robertson JI; Ball SG
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
[TBL] [Abstract][Full Text] [Related]
7. Effects of ketanserin on peripheral vascular pressor mechanisms in essential hypertension.
Elliott HL; Donnelly R; Reid JL
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S62-6. PubMed ID: 2459518
[TBL] [Abstract][Full Text] [Related]
8. Ketanserin: haemodynamic effects and mechanism of action.
Schalekamp MA; Woittiez AJ; Wenting GJ; van den Meiracker AH; Man in 't Veld AJ
J Hypertens Suppl; 1986 Apr; 4(1):S7-12. PubMed ID: 2871144
[TBL] [Abstract][Full Text] [Related]
9. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade.
van der Starre PJ; Reneman RS
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S54-61. PubMed ID: 2459516
[TBL] [Abstract][Full Text] [Related]
10. Differences in the chronic hypotensive mechanism of action of ketanserin in spontaneously hypertensive and Wistar-Kyoto rats.
Balasubramaniam G; Lee HS; Mah SC
J Hypertens; 1994 Jan; 12(1):7-14. PubMed ID: 8157947
[TBL] [Abstract][Full Text] [Related]
11. Renal hemodynamic effects of ketanserin therapy in essential hypertension.
Ram CV; Gonzalez DG; Kaplan NM; Ralakis JM; Henderson JD; Lugo CE; Zachariah N
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S78-80. PubMed ID: 2446078
[TBL] [Abstract][Full Text] [Related]
12. Potential vascular alpha1-adrenoceptor blocking properties of an array of 5-HT receptor ligands in the rat.
Centurión D; Mehotra S; Sánchez-López A; Gupta S; MaassenVanDenBrink A; Villalón CM
Eur J Pharmacol; 2006 Mar; 535(1-3):234-42. PubMed ID: 16545797
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
[TBL] [Abstract][Full Text] [Related]
14. Ketanserin and alpha 1-adrenergic antagonism in humans.
Zabludowski JR; Ball SG; Robertson JI
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S123-5. PubMed ID: 2412032
[TBL] [Abstract][Full Text] [Related]
15. Evidence for an alpha-1 receptor-mediated central sympathoinhibitory action of ketanserin.
McCall RB; Schuette MR
J Pharmacol Exp Ther; 1984 Mar; 228(3):704-10. PubMed ID: 6323678
[TBL] [Abstract][Full Text] [Related]
16. Peripheral and central cardiovascular effects of ketanserin in conscious normotensive rats.
Davy M; Midol-Monnet M; Heimburger M; Beslot F; Cohen Y
Arch Int Pharmacodyn Ther; 1987 Dec; 290(2):193-206. PubMed ID: 3128194
[TBL] [Abstract][Full Text] [Related]
17. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive properties of ketanserin (R 41 468).
Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
[TBL] [Abstract][Full Text] [Related]
19. Serotonergic mechanisms and blood pressure in sheep.
Nelson MA; Coghlan JP; Denton DA; Mills EH; Scoggins BA; Spence CD; Whitworth JA
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S117-9. PubMed ID: 2412029
[TBL] [Abstract][Full Text] [Related]
20. Ketanserin-induced baroreflex enhancement in spontaneously hypertensive rats depends on central 5-HT(2A) receptors.
Shen FM; Wang J; Ni CR; Yu JG; Wang WZ; Su DF
Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):702-7. PubMed ID: 17600544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
